Evidence map›Paper›PMID 42026073›Full record

Trial reportNature communications2026

Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.

Kamil A Rechache, Natalia S Nunes, Jennifer Sponaugle, Elisabetta Xue, Amy Chai, Rebecca Combs, Jessenia Campos, Xingmin Feng, Francis A Flomerfelt, Kalpana Upadhyaya and 19 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03922724 (Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03922724 phase2active not recruitingnot on this map

Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2019 to 2030Enrolled91ConditionsPeripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System DiseasesArmsATL-RIC, mRIC, allo HCT, RIC, GVHD prophylaxis
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Kamil A RechacheCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Natalia S NunesCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jennifer SponaugleCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Elisabetta XueCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Amy ChaiCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Rebecca CombsCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jessenia CamposCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Xingmin FengHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-8018-2366
Francis A FlomerfeltLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kalpana UpadhyayaDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
William TelfordLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Brian DawsonLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Thomas E HughesClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Syed Muhammad Salman ShahOffice of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Alicia PelusoFrederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Christi McKeownImmune Deficiency and Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Anita StokesImmune Deficiency and Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Scott NapierCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ruby SabinaCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jennifer WilderOffice of the Chief Medical Officer, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Kristen ColeOffice of the Chief Medical Officer, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Judy BaruffaldiOffice of the Chief Medical Officer, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Jennifer Cuellar-RodriguezNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Juan Gea-BanaclocheNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Mary M CzechNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Mustafa A HyderCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Christopher G KanakryCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Dimana DimitrovaCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Dimana.dimitrova@nih.gov.ORCID http://orcid.org/0000-0002-4868-6852
Jennifer A KanakryCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Jennifer.a.kanakry@medstar.net.ORCID http://orcid.org/0000-0001-9522-3618

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at 18% (95% CI 6-34%) at 3 years. Transplant-related mortality was 24% (95% CI 10-41%) at 1-year, low at 11% (95% CI 2-29%) for patients ≤60 years but 56% (95% CI 17-82%) for patients >60 years, p = 0.01. There was no grade III-IV acute graft-versus-host disease, while chronic graft-versus-host disease was estimated at 23% (95 CI 10-38%) at 2 years. This study demonstrates a benefit regardless of pre-transplantation disease status, challenging the requirement of remission for HCT.

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, Extranodal NK-T-CellLymphoma, T-Cell, PeripheralAdolescentAdultAgedFemaleGraft vs Host DiseaseHumansMaleMiddle AgedProspective StudiesTransplantation ConditioningTransplantation, HomologousYoung Adult

Identifiers

PMID42026073
PMCPMC13316028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.